Biosight Ltd.
Records under this name other than the patents Biosight Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Showing 1 to 6 of 6 · Back to Biosight Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,989,188 | Conjugates for cancer therapy and diagnosis Term ended Term ended Jan 16, 2026 · From the USPTO record | Term ended | Term ended Jan 16, 2026 | From the USPTO record |
| US 8,435,800 | Activated labeling reagents and methods for preparing and using the same Lapsed on the fee record Ended May 7, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 7, 2025 | From the USPTO record |
| US 8,993,278 | Conjugates for cancer therapy and diagnosis Term ended Ended no later than Feb 2, 2025 · From the USPTO record | Term ended | Ended no later than Feb 2, 2025 | From the USPTO record |
| US 7,135,547 | Peptide conjugated anti-cancer prodrugs Term ended Term ended Jul 9, 2022 · From the USPTO record | Term ended | Term ended Jul 9, 2022 | From the USPTO record |
| US 8,314,060 | Peptide conjugated anti-cancer prodrugs Term ended Term ended Mar 16, 2022 · From the USPTO record | Term ended | Term ended Mar 16, 2022 | From the USPTO record |
| US 7,638,127 | Peptide conjugated anti-cancer prodrugs Term ended Ended no later than Sep 5, 2021 · From the USPTO record | Term ended | Ended no later than Sep 5, 2021 | From the USPTO record |